Cargando…
Challenges in severe asthma: Do we need new drugs or new biomarkers?
Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biol...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550875/ https://www.ncbi.nlm.nih.gov/pubmed/36237537 http://dx.doi.org/10.3389/fmed.2022.921967 |